{{Rsnum
|rsid=460869
|Chromosome=20
|position=46449335
|Orientation=plus
|GMAF=0.393
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 7.1 | 51.3 | 41.6
| HCB | 8.8 | 43.8 | 47.4
| JPT | 13.3 | 45.1 | 41.6
| YRI | 55.8 | 36.7 | 7.5
| ASW | 45.6 | 50.9 | 3.5
| CHB | 8.8 | 43.8 | 47.4
| CHD | 9.3 | 38.0 | 52.8
| GIH | 14.9 | 47.5 | 37.6
| LWK | 61.8 | 31.8 | 6.4
| MEX | 6.9 | 51.7 | 41.4
| MKK | 50.0 | 39.1 | 10.9
| TSI | 10.8 | 41.2 | 48.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs460869
|Name_s=
|Gene_s=ZNF663
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. In combination, rs460869, rs6588131, and rs16965867 were all significant predictors of etoposide IC50, accounting for 30% of the variation in etoposide IC50 in the combined populations fo Caucasians and Yorubans. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00002. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109528
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs460869
|overall_frequency_n=65
|overall_frequency_d=128
|overall_frequency=0.507812
|n_genomes=40
|n_genomes_annotated=0
|n_haplomes=58
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}